SEC Tracker
Get the app
DYN · XBRL financial data

Dyne Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (DYN's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Research and development59*45629382*106999795*101152162
General and administrative9*25101315*16171721*242935
Total operating expenses68*697210697*122116114116*125182197
Other operating income (expense)(1)*1(0)(1)(0)*(0)(2)0(0)*(0)(0)(0)
Operating income (loss)(68)*(69)(72)(106)(97)*(122)(116)(114)(116)*(125)(182)(197)
Interest expense———0——03————
Other income (expense)1*4798*7564*434
Income tax expense (benefit)year only———year only———year only———
Net income (loss)(67)*(66)(65)(97)(90)*(115)(111)(108)(112)*(121)(179)(194)
Earnings per share, basic USD per share—(0.81)(0.70)(0.96)—(1.05)(0.97)(0.76)—(0.73)(1.08)(1.06)
Earnings per share, diluted USD per share—(0.81)(0.70)(0.96)—(1.05)(0.97)(0.76)—(0.73)(1.08)(1.06)

Balance sheet

CSV

Fiscal quarters (DYN's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents122272608532435472485574893753676913
Marketable securities1182171192207205199218217219222221
Prepaid and other current assets63513131712141416493942
Total current assets1294887927366596906988061,1271,0219381,176
Property and equipment, net5555566242424257
Right-of-use asset292827262524232221202019
Total assets1655228267696917217298671,1871,0809941,235
Accounts payable237267714128111215
Total current liabilities512230434234416051517891
Lease liability, non-current232221201918171615141513
Total liabilities744451636152158175215215292304
Accumulated deficit(633)(698)(763)(860)(950)(1,065)(1,176)(1,284)(1,396)(1,517)(1,696)(1,889)
Total stockholders' equity91478775706630669571692972865702931
Total liabilities and equity1655228267696917217298671,1871,0809941,235
Common shares outstanding (cover page) millions of shares8287100102113114142143165165187187

Cash flows

CSV

Fiscal quarters (DYN's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)(67)*(66)(65)(97)(90)*(115)(111)(108)(112)*(121)(179)(194)
Stock-based compensation6*207910*13111111*131516
Depreciation and amortization0*0000*1111*111
Net cash from operating activities(35)*(79)(55)*(75)*(84)*(106)(95)*(91)*(112)*(145)(130)*(177)*
Purchases of property and equipment0*01*0*1*10*0*0*02*2*
Net cash from investing activities26*(180)11*(19)*(16)*17*(38)*1*(2)(5)*(1)*
Proceeds from issuing common stock(0)*7424*0*0*1410*0*0*00*0*
Proceeds from long-term debtyear only——0*0*——0*49*——0*
Net cash from financing activities0*408380*18*4*141101*217*431*758*418*
Net change in cash(9)*150336*(76)*(97)*3713*89*320*(140)(77)*239*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Dyne Therapeutics913not reported(177)*187.4M6.4 quarters 10-QSep 30, 2026
Akebia Therapeutics156493.5*277.1M— 10-QJun 30, 2026
Viridian Therapeutics17326(93)*113.6M9.0 quarters 10-QSep 30, 2026
Collegium Pharmaceutical12920071*32.6M— 10-QJun 30, 2026
Neogen17222313218.3M— 10-QAug 31, 2026
Ardelyx461282.2*251.4M— 10-QSep 30, 2026
CorMedix25710286*77.9M— 10-QJun 30, 2026
Aurinia Pharmaceuticals468446*134.0M— 10-QSep 30, 2026
Harrow8471(9.8)*37.5M8.6 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.